Skip to main content

Fibrinogen Deficiency in Complex Cardiac Surgery

1
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
1
Haemocomplettan® PPhase 2/3
CSL Behring
CSL BehringIL - Bradley
1 program
Haemocomplettan® PPHASE_2_31 trial
Active Trials
NCT01124981Completed120Est. Dec 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CSL BehringHaemocomplettan® P

Clinical Trials (1)

Total enrollment: 120 patients across 1 trials

NCT01124981CSL BehringHaemocomplettan® P

Haemocomplettan® P During Elective Complex Cardiac Surgery

Start: Feb 2011Est. completion: Dec 2014120 patients
Phase 2/3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.